Brian Diekman, PhD

Brian Diekman, PhD

3300 Thurston Building
Campus Box 7280
Chapel Hill, NC 27599


Specialty Areas:  Tissue-engineering, stem cells, aging, murine models of osteoarthritis, genome editing

Chronology:  BS: Duke University (Biomedical Engineering), 2005; Ph.D.: Duke University (Biomedical Engineering), 2012; Post-doc: Duke University Medical Center (Orthopaedic Surgery, laboratory of Dr. Farshid Guilak) 2012-2014; Post-doc:  University of North Carolina (Lineberger Comprehensive Cancer Center, laboratory of Dr. Norman Sharpless): 2014-2017; Assistant Professor of Biomedical Engineering:  University of North Carolina and North Carolina State University, 2017-present.

Description of research and/or clinical interests:  Dr. Diekman has established a research laboratory that utilizes regenerative medicine technologies to develop novel therapeutic approaches for osteoarthritis.  One goal of the lab is to use engineered cartilage tissue as a model system to understand the mechanisms by which aging contributes to cartilage dysfunction and to screen for drugs that prevent cartilage dysfunction.  The lab also uses genome editing of stem cells to investigate the genetic risk factors for osteoarthritis.  In addition to experiments with cultured cells, work with rodent models allows the lab to test the feasibility of interventions designed to increase the regenerative capacity of cartilage tissue after injury.  

Selected Bibliography:

Loeser RF*, Collins JA, Diekman BO.  Ageing and the pathogenesis of osteoarthritis.  Nature Reviews Rheumatology. 2016 Jul;12(7):412-420. PMC4938009. *corresponding author  

Diekman BO*, Thakore PI*, O’Connor SK, Willard VP, Brunger JM, Christoforou N, Leong K, Gersbach CA, Guilak F.  Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells. Tissue Engineering Part A. 2015 Apr;21(7-8):1261-74. PMC4394871. *co-first authors.

Willard VP*, Diekman BO*, Sanchez-Adams J, Christoforou N, Leong KW, Guilak F.  Use of cartilage derived from mouse induced pluripotent stem cells for osteoarthritis drug screening. Arthritis & Rheumatology. 2014 Nov;66(11):3062-72.  PMC4308724.  *co-first authors.

Diekman BO, Christoforou N, Willard VP, Sun H, Sanchez-Adams J, Leong KW, Guilak F. Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells. Proceedings of the National Academy of Sciences USA. 2012 Nov 20;109(47):19172-7. PMC3511083.

Diekman BO, Wu CL, Louer CR, Furman BD, Huebner JL, Kraus VB, Olson SA, Guilak F. Intra-articular delivery of purified mesenchymal stem cells from C57BL/6 or MRL/MpJ superhealer mice prevents post-traumatic arthritis. Cell Transplantation. 2013;22(8):1395-408. PMC3891895.

Diekman BO, Rowland CR, Caplan AI, Lennon D, Guilak F. Chondrogenesis of adult stem cells from adipose tissue and bone marrow: Induction by growth factors and cartilage derived matrix. Tissue Engineering Part A. 2010 Feb;16(2):523-33. PMC2813149.

Diekman BO*, Estes BT*, Guilak F. The effects of BMP6 overexpression on adipose stem cell chondrogenesis: Interactions with dexamethasone and exogenous growth factors. Journal of Biomedical Materials Research Part A. 2010 Jun 1;93(3):994-1003. PMC3616877. *co-first authors.

Estes BT, Diekman BO, Gimble JM, Guilak F.  Isolation of adipose-derived stem cells and their induction to a chondrogenic phenotype. Nature Protocols. 2010 Jul;5(7):1294-311. PMC3219531.

Full publication list: https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/52097512/?sort=date&direction=ascending

 

Filed under: